Related Experiment Video
Updated: Aug 20, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients
Roberto Manfredi1, Leonardo Calza, Francesco Chiodo
1Department of Clinical and Experimental Medicine, Division of Infectious Diseases, University of Bologna 'Alma Mater Studiorum', S. Orsola Hospital, Bologna, Italy.
Abstract:
Ninety-seven consecutive patients started anti-HIV therapy based on efavirenz (46) or lopinavir-ritonavir (51) in an observational study. Despite the significantly more compromised immunological-clinical baseline conditions of patients starting lopinavir-ritonavir, a mean clinical-laboratory follow-up of 17 months showed a comparable laboratory response and therapy interruption or change rate, although the toxicity profile of the two compounds proved significantly different. Randomized studies comparing these two recommended first-line treatments are warranted, particularly from a pharmacoeconomic viewpoint.
Related Concept Videos
Retrovirus Life Cycles
Antiviral Nucleoside Inhibitors
Antiprotozoal Agents
Bioavailability Study Design: Healthy Subjects Versus Patients
Viral Hepatitis I: Introduction
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...

